DDInter1763 DDInter462
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Temsirolimus {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Temsirolimus {u} (Compound) upregulates {v} (Gene) NARFL
NARFL {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Temsirolimus {u} (Compound) downregulates {v} (Gene) LIG1
LIG1 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Temsirolimus {u} (Compound) upregulates {v} (Gene) TNFRSF21
TNFRSF21 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Temsirolimus {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Temsirolimus {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) regulates {v} (Gene) ERBB2
ERBB2 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Temsirolimus {u} (Compound) upregulates {v} (Gene) NARFL
NARFL {u} (Gene) is regulated by {v} (Gene) BRAF
BRAF {u} (Gene) is bound by {v} (Compound) Dabrafenib
Temsirolimus {u} (Compound) upregulates {v} (Gene) DUSP11
DUSP11 {u} (Gene) regulates {v} (Gene) SESN1
SESN1 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Temsirolimus (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Temsirolimus (Compound) upregulates NARFL (Gene) and NARFL (Gene) is upregulated by Dabrafenib (Compound)
Temsirolimus (Compound) downregulates LIG1 (Gene) and LIG1 (Gene) is downregulated by Dabrafenib (Compound)
Temsirolimus (Compound) upregulates TNFRSF21 (Gene) and TNFRSF21 (Gene) is downregulated by Dabrafenib (Compound)
Temsirolimus (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Temsirolimus (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) regulates ERBB2 (Gene) and ERBB2 (Gene) is upregulated by Dabrafenib (Compound)
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Temsirolimus (Compound) upregulates NARFL (Gene) and NARFL (Gene) is regulated by BRAF (Gene) and BRAF (Gene) is bound by Dabrafenib (Compound)
Temsirolimus (Compound) upregulates DUSP11 (Gene) and DUSP11 (Gene) regulates SESN1 (Gene) and SESN1 (Gene) is upregulated by Dabrafenib (Compound)